Octinoxate
Shade Uvaguard (octinoxate) is a small molecule pharmaceutical. Octinoxate was first approved as Shade uvaguard on 1992-12-07.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avobenzone
+
Octinoxate
+
Oxybenzone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SHADE UVAGUARD | Bayer | N-020045 DISCN | 1992-12-07 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ahc natural perfection fresh sun stick | OTC monograph final | 2023-06-13 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | F33.9 | — | 1 | 2 | 5 | 1 | 9 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 1 | — | 3 | — | 4 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | 2 | 1 | 3 | ||
| Dementia | D003704 | F03 | — | — | 1 | 1 | — | 2 | |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 2 | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | 2 | — | 2 |
| Tinnitus | D014012 | HP_0000360 | H93.1 | — | — | — | 1 | — | 1 |
| Brain concussion | D001924 | S06.0 | — | — | — | 1 | — | 1 | |
| Post-traumatic headache | D051298 | G44.3 | — | — | — | 1 | — | 1 | |
| Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | 1 | — | — | 2 |
| Psychophysiologic disorders | D011602 | F45.9 | — | — | 1 | — | — | 1 | |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | — | 1 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | — | — | 1 | — | — | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | 1 | 2 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | 2 | — | — | — | 2 |
| Temporomandibular joint disorders | D013705 | M26.6 | — | 2 | — | — | — | 2 | |
| Radiculopathy | D011843 | M54.1 | — | 1 | — | — | 1 | 2 | |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 2 | — | — | — | 2 |
| Vulvodynia | D056650 | N94.81 | — | 1 | — | — | — | 1 | |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | 1 | — | — | — | 1 |
| Chronic fatigue syndrome | D015673 | EFO_0004540 | G93.31 | — | 1 | — | — | — | 1 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | 1 | — | — | — | 1 |
| Back pain | D001416 | HP_0003418 | M54 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell carcinoma | D018288 | 1 | — | — | — | — | 1 | ||
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | OCTINOXATE |
| INN | octinoxate |
| Description | Octyl 4-methoxycinnamic acid is a cinnamate ester. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC(CC)COC(=O)C=Cc1ccc(OC)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 5466-77-3 |
| RxCUI | 13369 |
| ChEMBL ID | CHEMBL3183184 |
| ChEBI ID | — |
| PubChem CID | 5355130 |
| DrugBank | — |
| UNII ID | 4Y5P7MUD51 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 167 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,277 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more